Mercy Medical Center is expanding advanced treatment options for men with prostate cancer through the enhanced capabilities ...

"The number of men living with prostate cancer also continues to rise, so it's vital that we see investment in prostate ...

GenSci holds exclusive Chinese rights to Camcevi, covering central precocious puberty, premenopausal breast cancer, and ...

Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that it was notified by its licensing partner, Changchun GeneScience Pharmaceutical Co., Ltd. ("GenSci"), that China's National ...

ASX-listed healthcare companies are advancing new approaches to prostate cancer, spanning imaging, targeted therapies and ...

As the standards of care for prostate cancer change, new drugs, combination therapies, and trials enter the therapeutic space ...

Alicia Morgans, MD, explains how the ARACOG trial showed higher cognitive decline with enzalutamide vs darolutamide in ...

I f prostate cancer has spread to other areas of your body, your doctor may recommend androgen deprivation therapy (ADT), which halts the production of androgen hormones, especially testosterone.

For years, any man over 50 could ask his GP about having a simple blood test for signs of prostate cancer, known as a ...

Advanced prostate cancer is a form of prostate cancer that has spread or progressed beyond the prostate gland and has often requires long-term hormone-based treatment to slow disease growth. CAMCEVI ...

Men in England diagnosed with incurable advanced prostate cancer are more likely to survive for at least three years than ...

In addition to the NMPA's approval of CAMCEVI ® 42 mg for advanced prostate cancer described above, GenSci submitted a ...